The company has not filed an annual or quarterly report since its Q3 FY2019 10-Q, filed Nov 12, 2019. Its latest SEC filing is a 15-12B from Feb 20, 2020.
10-Q for Q3 FY2019, filed Nov 12, 2019
The sections below describe the company as of the FY2018 annual report.
Dispenses specialty medicines and provides infusion care for patients with complex chronic diseases, and offers pharmacy-benefit management services to health plans, employers and other payers.
10-K for FY2018, filed Mar 18, 2019We are the largest independent provider of specialty pharmacy and infusion services in the United States of America (“U.S.”). We are…View ↗
We provide specialty pharmacy services dedicated to servicing the needs of patients, while also providing clinical expertise…View ↗
In late 2017, we entered the PBM business through our December 2017 acquisition of LDI Holding Company, LLC, doing business as LDI…View ↗
The company sells prescription drugs through its specialty, mail and retail-network pharmacies. It earns money on home-delivery prescriptions when drugs arrive, and on pharmacy pickups or retail-network prescriptions when the claim is processed.
10-K for FY2018, filed Mar 18, 2019We provide specialty pharmacy services dedicated to servicing the needs of patients, while also providing clinical expertise…View ↗
The Company recognizes revenue from dispensing prescription drugs for home delivery at the time the drugs are physically delivered which is…View ↗
The Company provides a pharmacy benefit management service, including mail order pharmacy and specialty pharmacy services, to its clients…View ↗
$5.5B
10-K for FY2018, filed Mar 18, 2019
$5.5B ↗
Patients receive specialty drugs at home or through physicians’ offices; prescribers refer patients, while managed care organizations, employer groups, unions and plan administrators contract for pharmacy-benefit services. Hospitals and health systems also partner with Diplomat for specialty-pharmacy support.
10-K for FY2018, filed Mar 18, 2019We provide specialty pharmacy services dedicated to servicing the needs of patients, while also providing clinical expertise…View ↗
· Hospital and Health System Services: We provide clinical and administrative support services to hospitals and health systems that…View ↗
In late 2017, we entered the PBM business through our December 2017 acquisition of LDI Holding Company, LLC, doing business as LDI…View ↗
(2) establishing, maintaining and strengthening relationships with prescribers and key opinion leaders to obtain prescription referrals…View ↗
Not on paper. It lost $302.3M in FY2018, but brought in more cash than it spent: $33.9M of free cash flow.
10-K for FY2018, filed Mar 18, 2019
10-K for FY2018, filed Mar 18, 2019
−$267.3MView ↗
10-K for FY2018, filed Mar 18, 2019
−$302.3MView ↗
10-K for FY2018, filed Mar 18, 2019
$33.9MView ↗
Grew. Revenue grew 2.5x in 4 years, from $2.2B in FY2014 to $5.5B in FY2018, about 25% a year.
Added pharmacy-benefit management
The older report framed Diplomat as a specialty pharmacy company independent of pharmacy-benefit management. The latest report also describes pharmacy-benefit services, from prescription-claim handling to retail networks, mail-order pharmacy and drug-plan support.
10-K for FY2015, filed Feb 29, 2016 10-K for FY2018, filed Mar 18, 2019We are the largest independent specialty pharmacy in the United States, and are focused on improving the lives of patients with complex…View ↗
Competes with CVS Caremark, Express Scripts, and Walgreens
10-K for FY2018, filed Mar 18, 2019We are the largest independent provider of specialty pharmacy services in the U.S., with a market share of more than 2 percent (based on…View ↗
Loading...
